1. The **Boston Scientific** of specialized, minimally invasive devices for peripheral vascular disease and tumor ablation.

2. A focused **Medtronic** for innovative medical technologies in vascular care and oncology.

• Thrombectomy Systems: Devices like AngioVac and Auryon used to remove blood clots from the body.
• Vascular Access Devices: A range of catheters, including PICCs, midlines, and ports, designed for long-term intravenous access.
• Tumor Ablation Systems: Technologies such as Solero Microwave Ablation and NanoKnife, utilized for the targeted destruction of tumors.
• Drainage Catheters: Medical devices designed for the percutaneous drainage of fluids from various body cavities.

AngioDynamics (ANGO) sells primarily to other companies within the healthcare sector, rather than directly to individuals.

The company markets and sells its medical devices to a diversified customer base, primarily consisting of:

• Hospitals: These are a core customer segment, utilizing AngioDynamics' products in various departments such as interventional radiology, oncology, and vascular surgery.
• Clinics and Alternate Site Facilities: This category includes specialized clinics, outpatient surgical centers, and other healthcare facilities where medical procedures using AngioDynamics' devices are performed.
• Distributors: Internationally, AngioDynamics also sells its products through a network of independent distributors who then supply them to local healthcare providers.

AngioDynamics does not disclose specific major customer companies by name in its public filings, such as its annual 10-K reports. This indicates that its revenue is not concentrated with any single customer or a small group of customers, but rather is diversified across a broad base of healthcare institutions and distributors. Therefore, no specific public company customer names or symbols can be listed as major customers.

null

James C. Clemmer, President and Chief Executive Officer

Mr. Clemmer has served as President and Chief Executive Officer of AngioDynamics Inc. since April 2016. Before joining AngioDynamics, he was the President of the $1.8 billion medical supplies segment at Covidien PLC, where he was responsible for strategic and day-to-day operations across 23 product categories globally. Earlier in his career, he served as Group President at Kendall Healthcare, managing the U.S. business across five divisions and developing the strategic plan for the Medical Supplies segment before its spin-off from Tyco. Mr. Clemmer began his career at Sage Products, Inc., which was acquired by Covidien in 1999. He currently serves on the Board of Directors for AngioDynamics and Lantheus Medical Imaging.

Stephen A. Trowbridge, Executive Vice President and Chief Financial Officer

Mr. Trowbridge was appointed Executive Vice President and Chief Financial Officer in February 2020, having previously served as Interim Chief Financial Officer since October 2019. He joined AngioDynamics in June 2008 as Corporate Counsel and later served as Senior Vice President and General Counsel. Prior to AngioDynamics, Mr. Trowbridge was Corporate Counsel at Philips Healthcare and Intermagnetics General Corporation. He started his career in the Mergers and Acquisitions and Securities Group at Cadwalader, Wickersham & Taft LLP.

Laura Piccinini, Senior Vice President/General Manager, Cardiovascular & International

Ms. Piccinini joined AngioDynamics in June 2021. She has over 25 years of leadership experience in the Medical Device/Technology industry, with a strong background in respiratory care. Most recently, she was CEO and a board member for Respiratory Motion, Inc., and Global Head of Commercial Operations for the Implants business unit at Nobel Biocare Systems (Danaher Company/Envista IPO). Her prior roles include serving as President of EMEA at both Covidien and Stryker.

Benjamin Davis, Senior Vice President, Business Development, Strategy and R&D

Mr. Davis serves as the Senior Vice President, Corporate Development and Strategy of AngioDynamics.

Chad T. Campbell, Senior Vice President and General Manager, Global Vascular Access

Mr. Campbell has served as Senior Vice President of Vascular Access of AngioDynamics Inc. since May 2016. He is also listed as SVP & GM, Global Vascular Access.

The success and rapid market penetration of companies like Inari Medical, particularly with their FlowTriever and ClotTriever systems for mechanical thrombectomy in venous thromboembolism (VTE), represent a clear emerging threat to AngioDynamics' AngioVac system. AngioVac is a critical product for AngioDynamics, used for the aspiration of intraluminal thrombi. Inari Medical's dedicated and highly effective solutions for large-volume clot removal in the venous system directly compete with and increasingly challenge AngioDynamics' presence in this important market segment, potentially limiting AngioVac's growth and market share.

AngioDynamics (NASDAQ: ANGO) operates in several key medical technology markets, offering devices for peripheral artery disease, thrombus management, and interventional oncology. The addressable markets for their main products and services are sized as follows:

• Peripheral Artery Disease (PAD) Devices (including Auryon Atherectomy System): The global peripheral artery disease market size was estimated at USD 7.3 billion in 2024 and is projected to reach USD 11.3 billion by 2033, growing at a CAGR of 5.2% from 2025 to 2033. North America held the largest share of this global market, accounting for 43.5% in 2024. The global laser atherectomy devices market, a segment within PAD treatment that includes AngioDynamics' Auryon system, had North America as its leading region in 2022 due to the high prevalence of PAD, advanced healthcare infrastructure, and adoption of minimally invasive procedures. The overall atherectomy devices market size was valued at USD 1.03 billion in 2024 and is expected to reach USD 1.93 billion by 2032 globally, with North America holding a 47.5% share in 2024. The U.S. peripheral vascular devices and accessories market size was estimated at USD 3.6 billion in 2024.
• Thrombus Management Devices (including AngioVac and AlphaVac): The global thrombectomy devices market size was valued at USD 1.37 billion in 2024 and is forecasted to reach USD 2.60 billion by 2033, growing at a CAGR of 7.4% during the forecast period (2025-2033). Another report estimates the mechanical thrombectomy devices market, which includes AngioDynamics' AngioVac and AlphaVac, to be valued at USD 1.51 billion in 2024 and predicted to reach USD 2.99 billion by 2034, growing at a 7.2% CAGR from 2025-2034. North America dominated the market for mechanical thrombectomy devices in 2023. The venous thromboembolism (VTE) market was projected to grow from $950 million in 2020 to $1.7 billion by 2027 globally, with an 8.7% annual growth.
• Interventional Oncology Products (including NanoKnife System): The global interventional oncology market size was valued at USD 2.18 billion in 2024 and is projected to grow to USD 4.04 billion by 2032, exhibiting a CAGR of 8.1% from 2025 to 2032. Another report states the global interventional oncology market size was estimated at USD 2.7 billion in 2024 and is projected to reach USD 4.38 billion by 2030, growing at a CAGR of 8.55% from 2025 to 2030. North America held the largest share of the interventional oncology market, accounting for 42.2% in 2024 and 41.87% in 2024. The U.S. market within North America is anticipated to experience lucrative growth.

• Growth in Mechanical Thrombectomy (AlphaVac and AngioVac): AngioDynamics expects continued strong year-over-year growth from its mechanical thrombectomy businesses, specifically AlphaVac and AngioVac. AlphaVac sales have shown significant sequential growth, and the AlphaVac F18 System received FDA clearance for treating pulmonary embolism (PE), expanding its addressable market. The company is also investing in an expanded Mechanical Thrombectomy sales force to support this growth, and the RECOVER AV clinical trial for AlphaVac in Europe is underway.
• Expansion and Adoption of NanoKnife: The NanoKnife platform is anticipated to be a significant contributor to future revenue. Total NanoKnife revenue has shown strong increases, with particularly robust growth in probe sales. Key commercial and clinical catalysts include the NanoKnife prostate FDA indication (expected December 2024) with a new CPT code effective January 1, 2025, which is expected to accelerate the adoption of higher-margin products.
• Continued Performance of the Auryon Atherectomy System: Auryon has demonstrated consistent double-digit growth over multiple consecutive quarters and is expected to continue as a solid contributor to AngioDynamics' growth. The AMBITION BTK trial for Auryon is also expected to begin enrollment soon, which could further drive its market presence and revenue.
• Overall MedTech Segment Expansion and Market Demand for Minimally Invasive Therapies: AngioDynamics has strategically transformed by divesting non-core assets and focusing on its high-growth MedTech segment. This segment has consistently shown strong growth and is projected to continue its upward trajectory, with expected net sales growth of 14% to 16% in fiscal year 2026. Analysts concur that growth will be propelled by increasing global demand for minimally invasive therapies.

Share Repurchases

• AngioDynamics announced a share repurchase program for up to $15.0 million of its outstanding common shares subsequent to fiscal year 2024.
• As of February 28, 2025, $13.3 million remained available under the $15.0 million authorized share repurchase program.
• The company repurchased shares in fiscal years 2024 and 2025.

Share Issuance

• The number of shares outstanding for AngioDynamics increased by 1.49% in one year prior to November 2025.
• Proceeds from the exercise of stock options and employee stock purchase plans were $43,000 in the first quarter of fiscal year 2025 and $234,000 in the first quarter of fiscal year 2026.

Outbound Investments

• In February 2024, AngioDynamics sold its PICC and Midline product portfolios to Spectrum Vascular for up to $45 million in cash, which included an upfront payment, an earnout, and a milestone payment.
• The company divested its Dialysis and BioSentry businesses for $100 million in cash in June 2023.
• AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC on July 27, 2021.

Capital Expenditures

• Capital expenditures were -$9.82 million in the last 12 months prior to November 2025.
• Historical capital expenditures were $4.30 million in fiscal year 2024, $3.81 million in fiscal year 2023, and $2.52 million in fiscal year 2022.
• AngioDynamics projects capital expenditures of $5 million for fiscal year 2026 and $6 million annually for fiscal years 2027-2030, representing approximately 2% of revenue.